NL
DE
Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Source: https://www.aiosyn.com/news/take-off-2-early-phase-funding/
Related news items
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Aiosyn selected as finalist for OostNL's Startversneller vote now!
18 October 2022The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.
read more.aspx?width=800&height=534&ext=.jpg&type=BlockColumn1Zoom1)
Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm
4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides. read more
LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics
7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor. read more
